Avastin, the wonder drug which has been the last resort for many women suffering metastatic breast cancer, risked being disapproved by the FDA last December. Obviously, this is not good news for many advance-stage breast cancer patients.
Nearly 17,500 women rely on Avastin, an advanced stage breast cancer drug that helps reduce blood flow to tumors , thus slowing their growth, and even completely wiping out the tumors in some cases. Therefore, the drug helps women survive much longer.
Avastin is expensive and patients need to spend more than $90,000 a year on treatment.